Search
President Trump has threatened to impose steep tariffs on imported drugs, asserting that this measure could bring down drug prices and bolster national security. However, industry insiders caution that these tariffs might not achieve their intended objectives due to intricate supply chains and high domestic production costs. Instead, they warn that the policy could foster uncertainty within the pharmaceutical sector. Consequently, U.S. pharmaceutical stocks experienced a general decline. In response, several pharmaceutical companies announced plans to increase domestic investments in an effort to circumvent the tariffs. Nevertheless, experts emphasize that this approach might not necessarily diminish dependence on imported pharmaceutical ingredients or translate into lower consumer costs.
-
C114 Communication Network -
Communication Home
